|
Inhibitors of TRIP8b for Novel Mood Disorder Therapeutics
SHORT DESCRIPTION
Novel inhibitors that disrupt TRIP8b-HCN binding to offer an alternative antidepressant mechanism for treatment of mood disorders.
INVENTORS
Gary Schiltz*
Weinberg College of Arts and Sciences, Department of Chemistry
Dane Chetkovich
Ye Han
Iredia Iyamu
Kyle Lyman
*...
Published: 6/17/2026
|
Updated: 6/17/2026
|
Inventor(s):
Keywords(s): Antidepressant, BIO2026, Depression, Mood disorder, Neurologic disease, Neurology, Psychiatric disorder, Targeted therapy, Therapeutics
Category(s): Life Sciences > Therapeutics
|
|
Bioactive Supramolecular Peptide Amphiphile Platforms for CNS In Vitro Models, CNS Regeneration, and Neurotherapeutic Delivery
SHORT DESCRIPTION
A suite of self‑assembling peptide amphiphile nanostructures and hydrogels that mimic key neurotrophic factors, modulate ionic and electrical microenvironments, and protect therapeutic peptides to enhance neural survival, maturation, and regeneration across CNS diseases and injuries
INVENTORS
Samuel I Stupp
Weinberg...
Published: 7/1/2026
|
Updated: 6/16/2026
|
Inventor(s):
Keywords(s): AD - Alzheimer’s Disease, ALS - Amyotrophic Lateral Sclerosis, BIO2026, Biomaterials, CNS - Central Nervous System, Drug delivery, Drug discovery, Drug screening, Hydrogel, In vitro models, Neurology, PD - Parkinson's Disease, Regenerative medicine, Research tool, Scaffold, SCI - Spinal cord injury, Smart/Functional materials, Therapeutics
Category(s): Life Sciences > Healthcare Devices, Tools & IT > Neurology, Life Sciences > Therapeutics
|
|
A CSF-Derived Therapy for Psychiatric Disorders
SHORT DESCRIPTION
A synthetic soluble ⍺2δ-1-Fc protein to restore brain function in schizophrenia and autism.
INVENTORS
Peter Penzes*
Northwestern University Feinberg School of Medicine, Department of Physiology
Marc Dos Santos
* Principal Investigator
NU Tech ID: NU 2023-196
IP STATUS
US...
Published: 6/16/2026
|
Updated: 6/10/2026
|
Inventor(s):
Keywords(s): ASD - Autism Spectrum Disorder, BIO2026, Biologic, Neurologic disease, Neurology, PSD - Psychotic spectrum disorder, Psychiatric disorder, Schizophrenia, Therapeutics
Category(s): Life Sciences > Therapeutics
|
|
Novel Aminotransferase Inhibitor Platform for the Treatment of Cancer and Neurological Disorders
SHORT DESCRIPTION
Novel Aminotransferase Mechanism-Based Inhibitor (MBI) Platform Targeting OAT and GABA-AT as Novel Treatments for Cancer and Neurological Disorders.
INVENTORS
Richard Silverman*
Weinberg College of Arts and Sciences, Department of Chemistry
* Principal Investigator
DEVELOPMENT...
Published: 6/17/2026
|
Updated: 6/1/2026
|
Inventor(s):
Keywords(s): AD - Alzheimer’s Disease, BIO2026, Cancer/Oncology, CNS - Central Nervous System, Colon cancer, Epilepsy, Gastric cancer, Liver cancer, Lung cancer, Neurodegenerative disease, Neurologic disease, Neurology, Pancreatic cancer, PD - Parkinson's Disease, Psychiatric disorder, Small molecule, Targeted therapy, Therapeutics
Category(s): Life Sciences > Therapeutics
|
|
Northwestern Startup: Akava Therapeutics
Founded: 2019
Northwestern Inventor:
Richard Silverman
Weinberg College of Arts and Sciences
Department of Chemistry and Department of Molecular Biosciences
Feinberg School of Medicine
Department of Pharmacology
AKAVA Therapeutics is developing first-in-class small molecule therapeutics that inhibit enzymes, inhibit cancer, and inhibit protein...
Published: 5/13/2026
|
Updated: 5/13/2026
|
Inventor(s):
Keywords(s): ALS - Amyotrophic Lateral Sclerosis, Neurodegenerative disease, Neurology, Therapeutics
Category(s): Life Sciences > Therapeutics
|
|
Antisense Oligonucleotides to Prevent Genetic Mis-Splicing for ALS/FTD Therapeutics
SHORT DESCRIPTION
Antisense oligonucleotides (ASOs) that correct TDP‑43–dependent mis‑splicing of KCNQ2 thereby reducing neuronal hyperexcitability in ALS/FTD and related TDP‑43 proteinopathies.
INVENTORS
Evangelos Kiskinis*
Northwestern University Feinberg School of Medicine, Department of Neurology
Jonathan...
Published: 6/16/2026
|
Updated: 5/7/2026
|
Inventor(s):
Keywords(s): ALS - Amyotrophic Lateral Sclerosis, BIO2026, FTD - Frontotemporal Dementia, Neurodegenerative disease, Neurologic disease, Neurology, Nucleic Acids, Rare diseases, Targeted therapy, Therapeutics
Category(s): Life Sciences > Therapeutics
|
|
GDNF-Mimetic Self-Assembling Supramolecular Nanostructure to Enhance Survival and Function of Dopaminergic Neurons for Treatment of Parkinson's Disease
NU 2024-175
SHORT DESCRIPTION
A self-assembling bioactive matrix that presents GDNF-mimetic peptides to support the viability, maturation, and function of dopaminergic neurons in cell replacement therapy for treatment of Parkinson’s Disease.
INVENTORS
Samuel Stupp*
Weinberg College of Arts and Sciences, Department...
Published: 6/16/2026
|
Updated: 4/30/2026
|
Inventor(s):
Keywords(s): BIO2026, Biologic, Biomaterials, Cell delivery, CNS - Central Nervous System, CVA - Cerebrovascular Accident, Nanomaterials, Neurodegenerative disease, Neurologic disease, Neurology, PD - Parkinson's Disease, Scaffold, SCI - Spinal cord injury, TBI - Traumatic brain injury, Therapeutics
Category(s): Life Sciences > Therapeutics, Life Sciences > Biomarkers & Biomedical Research Tools, Life Sciences > Healthcare Devices, Tools & IT > Neurology
|
|
Bioactive, Conductive, and Antioxidant Supramolecular Polymer Hydrogels for Neural Applications
SHORT DESCRIPTION
Biomaterial scaffold for neural cell culture and therapeutic implants that harnesses bioactive, conductive, and antioxidant properties to boost neural cell viability and maturation.
INVENTORS
Samuel Stupp*
Weinberg College of Arts and Sciences, Department of Chemistry
Anna Metlushko
Bo...
Published: 6/16/2026
|
Updated: 4/30/2026
|
Inventor(s):
Keywords(s): BIO2026, Biologic, Biomaterials, CNS - Central Nervous System, Implantable devices, Neurology, Regenerative medicine, Scaffold, SCI - Spinal cord injury, Smart/Functional materials
Category(s): Life Sciences > Biomarkers & Biomedical Research Tools, Life Sciences > Healthcare Devices, Tools & IT > Neurology, Life Sciences > Therapeutics
|
|
Selective PAD2 Inhibitors for Neuroprotection in Traumatic Brain Injury
SHORT DESCRIPTION
Novel PAD2-selective inhibitor platform targeting neuroinflammation to support both acute neuroprotection and long-term functional recovery as a first-in-class treatment of traumatic brain injury.
INVENTORS
Hasan Alam*
Northwestern University Feinberg School of Medicine, Department of Surgery (Trauma...
Published: 6/16/2026
|
Updated: 4/27/2026
|
Inventor(s):
Keywords(s): BIO2026, CNS - Central Nervous System, CVA - Cerebrovascular Accident, Neurodegenerative disease, Neuroinflammation, Neurologic disease, Neurology, Small molecule, Targeted therapy, TBI - Traumatic brain injury, Therapeutics
Category(s): Life Sciences > Therapeutics
|
|
Biomolecular Condensates as Protein Degradation Tools for Intracellular Targets
SHORT DESCRIPTION
A targeted-protein degradation platform for intracellular targets, addressing resistant oncogenic and neurodegenerative targets.
INVENTORS
Shana Kelley*
Weinberg College of Arts & Sciences, Department of Chemistry
Yi Li
* Principal Investigator
NU Tech ID: NU 2025-050
IP...
Published: 6/16/2026
|
Updated: 4/27/2026
|
Inventor(s):
Keywords(s): AD - Alzheimer’s Disease, BIO2026, Biologic, Biomolecular condensates, Cancer/Oncology, Drug delivery, Nanoparticle, Neurodegenerative disease, Neurologic disease, Neurology, PD - Parkinson's Disease, Platform technology, Targeted protein degradation, Targeted therapy, Therapeutics
Category(s): Life Sciences > Therapeutics, Life Sciences > Biomarkers & Biomedical Research Tools
|